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BSTRACT
The American College of Cardiology Foundation
ACCF), in partnership with key specialty and subspecialty
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Volume 56, Number 1 Mohler III et al e19societies, conducted a review of common clinical scenarios
where noninvasive vascular testing (ultrasound and physi-
ological testing) is frequently considered. The indications
(clinical scenarios) were derived from common applications
or anticipated uses, as well as from current clinical practice
guidelines and results of studies examining the implemen-
tation of the original appropriate use criteria (AUC). The
159 indications in this document were developed by a
diverse writing group and scored by a separate independent
technical panel on a scale of 1 to 9, to designate appropriate
use (median 7 to 9), uncertain use (median 4 to 6), and
inappropriate use (median 1 to 3).
A total of 255 indications (with the inclusion of
surveillance timeframes) were rated. One hundred and
seventeen indications were rated as appropriate, 84 were
rated as uncertain, and 54 were rated as inappropriate.
The AUC for peripheral vascular disease have the poten-
tial to impact physician decision making, healthcare deliv-
ery, and reimbursement policy. Furthermore, recognition
of uncertain clinical scenarios facilitates identification of
areas that would benefit from future research.
PREFACE
In an effort to respond to the need for the rational use
of imaging services in the delivery of high-quality care, the
ACCF has undertaken a process to determine the appropri-
ate use of cardiovascular imaging for selected patient indi-
cations. AUC publications reflect an ongoing effort by the
ACCF to critically and systematically create, review, and
categorize clinical situations where diagnostic tests and
procedures are utilized by physicians caring for patients
with cardiovascular diseases. The process is based on cur-
rent understanding of the technical capabilities of the im-
aging modalities examined. Although impossible to be
entirely comprehensive given the wide diversity of clinical
disease, the indications are meant to identify common
scenarios encompassing the majority of situations encoun-
tered in contemporary practice. Given the breadth of infor-
mation they convey, the indications do not directly corre-
spond to theNinthRevision of the International Classification
of Diseases (ICD-9) system as these codes do not include
clinical information, such as symptom status.
The ACCF believes that careful blending of a broad
range of clinical experiences and available evidence-based
information will help guide a more efficient and equitable
allocation of healthcare resources in cardiovascular imag-
ing. The ultimate objective of AUC is to improve patient care
and health outcomes in a cost-effective manner, but it is not
intended to ignore ambiguity and nuance intrinsic to clinical
decision making. AUC thus should not be considered substi-
tutes for sound clinical judgment and practice experience.
We are grateful to the technical panel, a professional
group with a wide range of skills and insights, for their
thoughtful and thorough deliberation of the merits of
peripheral vascular ultrasound for various indications. We
would also like to thank the 24 individuals who provided a
careful review of the draft of indications, the parent AUC
Task Force, and the ACC staff, Joseph Allen and Jenissa baidari for their exceptionally skilled support in the gener-
tion of this document.
Emile R. Mohler III, MD, FACC
Chair, Peripheral Vascular Ultrasound and Physiological
Testing
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force
. INTRODUCTION
Improvements in cardiovascular imaging technology
nd their application, coupled with increasing therapeutic
ptions for cardiovascular disease, have led to an increase in
ardiovascular imaging. Diagnostic imaging services reim-
ursed under Medicare’s physician fee schedule grew more
apidly than any other type of physician service from 1999
o 2003, although more recently, the rate of imaging
olume growth in Medicare has been slowing. Still, the
rmamentarium of noninvasive diagnostic tools has ex-
anded greatly, offering a variety of new and more sophis-
icated imaging techniques. As imaging technology and
linical applications continue to advance, the healthcare
ommunity needs to understand how to best incorporate
hese technologies into daily clinical care and how to
hoose between new and long-standing established imag-
ng technologies. In an effort to respond to this need and to
nsure the effective use of advanced diagnostic imaging
ools, the Appropriate Use Criteria (AUC) project was
nitiated.
. METHODS
The indications included in this publication cover a
ide array of cardiovascular signs and symptoms as well as
linical judgments as to the likelihood of cardiovascular
ndings. Within each main disease category, a standardized
pproach was used to capture the majority of clinical sce-
arios without making the list of indications excessive.
The indications were constructed by experts in periph-
ral vascular disease and in other fields and were modified
n the basis of discussions among the task force and feed-
ack from independent reviewers and the technical panel.
herever possible, indications were mapped to relevant
linical guidelines and key publications/references where
vailable in the medical literature (Online Appendix).
A detailed description of the methods used for ranking
he selected clinical indications is found in a previous pub-
ication, “ACCF Proposed Method for Evaluating the Ap-
ropriateness of Cardiovascular Imaging”.1 Briefly, this
rocess combines evidence-based medicine and practice
xperience by engaging a technical panel in a modified
elphi exercise.
The technical panel first rated indications indepen-
ently. Then, the panel was convened for a face-to-face
eeting for discussion of each indication. At this meeting,
anel members were provided with their scores and a
linded summary of their peers’ scores. After the meeting,
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their final scores for each indication.
Although panel members were not provided explicit
cost information to help determine their appropriate use
ratings, they were asked to implicitly consider cost as an
additional factor in their evaluation of appropriate use. In
rating these criteria, the technical panel was asked to assess
whether the use of the test for each indication is appropri-
ate, uncertain, or inappropriate, and was provided the
following definition of appropriate use:
An appropriate imaging study is one in which the ex-
pected incremental information, combined with clinical
judgment, exceeds the expected negative consequence*
by a sufficiently wide margin for a specific indication that
the procedure is generally considered acceptable care and
a reasonable approach for the indication.
The technical panel scored each indication as follows:
Median Score 7 to 9
Appropriate test for specific indication (test is generally
acceptable and is a reasonable approach for the indication).
Median Score 4 to 6
Uncertain for specific indication (test may be generally
acceptable and may be a reasonable approach for the indi-
cation). Uncertainty also implies that more research and/or
patient information is needed to classify the indication
definitively.
Median Score 1 to 3
Inappropriate test for that indication (test is not generally
acceptable and is not a reasonable approach for the indica-
tion).
The division of these scores into 3 levels of appropri-
ateness is somewhat arbitrary, and the numeric designa-
tions should be viewed as a continuum. Further, there is
diversity in clinical opinion for particular clinical scenarios,
such that scores in the intermediate level of appropriate use
should be labeled “uncertain,” as critical patient or research
data may be lacking or discordant. This designation should
be a prompt to the field to carry out definitive research
investigations whenever possible. It is anticipated that the
AUC reports will continue to be revised as further data are
generated and information from the implementation of the
criteria is accumulated.
To prevent bias in the scoring process, the technical
panel was deliberately comprised of a minority of specialists
in vascular noninvasive testing. Specialists, although offer-
ing important clinical and technical insights, might have a
natural tendency to rate the indications within their spe-
cialty as more appropriate than nonspecialists.1 In addition,
care was taken in providing objective, nonbiased informa-
tion, including guidelines and key references, to the tech-
nical panel.
The level of agreement among panelists as defined by
RAND2 was analyzed based on the BIOMED rule for a
*Negative consequences include the risks of the procedure (ie, radiation or
contrast exposure) and the downstream impact of poor test performance
such as delay in diagnosis (false negatives) or inappropriate diagnosis (false
positives).anel of 14 to 16 members. As such, agreement was defined
s an indication where 4 or fewer panelists’ ratings fell
utside the 3-point region containing the median score.
Disagreement was defined as where at least 5 panelists’
atings fell in both the appropriate and the inappropriate
ategories. Any indication having disagreement was cate-
orized as uncertain regardless of the final median score.
ndications that met neither definition for agreement or
isagreement are in a third, unlabeled category.
. ASSUMPTIONS
To prevent any inconsistencies in interpretation, spe-
ific assumptions are provided that were considered by the
echnical panel in rating the relevant clinical indications for
he appropriate use of peripheral vascular ultrasound and
hysiological testing.
A peripheral vascular ultrasound and physiological test-
ng examination and report will include:
1. Performance of the vascular ultrasound or physiologi-
cal testing examination using a standardized scanning
protocol and standardized documentation of gray-
scale (B-mode) color flow and spectral Doppler wave-
form images as required for the specific test type.
Scanning protocols may be developed by the labora-
tory based upon laboratory-specific considerations and
techniques as well as recommended technical elements
per appropriate organizations (eg, American Institute
of Ultrasound in Medicine, Society of Vascular Ultra-
sound) or laboratory accrediting organizations (Inter-
societal Commission for the Accreditation of Vascular
Laboratories, ICAVL, or American College of Radiol-
ogy, ACR).3
2. Interpretation of the vascular ultrasound or physiolog-
ical testing examination by a physician interpreter us-
ing standard, laboratory specific diagnostic criteria
that have been developed by the laboratory or adapted
from the ultrasound literature and are validated inter-
nally for accuracy as part of ongoing quality assurance
programs. It is implicit that diagnostic criteria will vary
across laboratories, but adherence to pre-defined cri-
teria within a laboratory is required. Laboratory-
specific protocols should be compiled in written policy
and procedure manuals that are made available to
medical and technical staff for review and discussion.
3. Appropriate equipment is used for each specific type of
testing, including appropriate frequency ultrasound
transducers and appropriately sized cuffs for physio-
logical testing.
4. Documentation that the vascular sonographer used
optimal angle correction techniques to ensure accurate
angle of insonation for reporting of Doppler velocity
measurements. In general, an angle of insonation of 60
degrees or less is used with appropriate sample volume
placement.
5. All standard vascular ultrasound and physiological
testing techniques have a sensitivity and specificity
11
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the specific examination type.
6. Testing should be performed by a credentialed tech-
nologist (RVT or RVS) and interpreted by a creden-
tialed physician (RPVI or ACR). Finally, the testing
should be done in an accredited facility (ICAVL or
ACR).
7. If prior testing is of poor technical quality, repeat
imaging may sometimes be appropriate in a different
facility or after the conditions that restricted the prior
testing are no longer present (eg, bowel gas, open
wounds) prior to the specified timeframes.
8. The appropriate use of testing is assumed to have the
potential to impact clinical decision making and to
direct therapeutic interventions.
9. The range of potential indications for vascular ultra-
sound and physiological testing is quite large, particu-
larly in comparison with other cardiovascular imaging
tests. Thus, the indications are, at times, purposefully
broad to cover an array of vascular signs and symptoms
as well as the ordering physician’s best judgment as to
the presence of vascular abnormalities. Additionally,
there are likely clinical scenarios that are not covered
by the current indications in this document.
10. For all stress physiological testing, the mode of stress
testing is assumed to be exercise for patients able to
exercise. Laboratory-specific protocols should specify
the precise form of exercise protocol used (eg, tread-
mill walking exercise protocol indicating speed and
grade of treadmill settings and the specifics of other
forms of exercise testing).
11. Complete vascular examinations, vascular ultrasound
and physiological testing, require bilateral studies in
the majority of clinical cases (such as carotid duplex
examination, renal duplex examination, lower extrem-
ity physiologic testing), unless specific clinical indica-
tions warrant a limited study (eg, surveillance follow-
ing unilateral lower extremity revascularization).
12. Carotid duplex ultrasound refers to testing protocols
for evaluation of the extracranial cerebrovasculature
only and does not include transcranial Doppler or
transcranial duplex examinations.
13. To optimize patient care and minimize need for un-
necessary repeat studies, it is generally recommended
that repeat or serial scans (eg, for surveillance of
asymptomatic carotid artery stenosis) be performed in
the same facility.
14. Raters were instructed to consider cost implicitly when
making the appropriate use determination.
15. Raters were instructed to consider patient safety im-
plicitly in the appropriate use determination.
16. If the reason for a test can be assigned to more than 1
clinical indication, it should be matched to the indica-
tion with the highest appropriate use score.
17. For each indication, the rating should reflect whether
the test is reasonable for the patient according to the
appropriate use definition, not whether the test is the
better or worse than another.8. The category of “uncertain” should be used when insuf-
ficient clinical data are available for a definitive categori-
zation or when there is disagreement as defined in the
Methods section. The designation of “uncertain” is as-
sumed to not provide grounds for denial of reimbursement.
9. When multiple timeframes are presented for surveil-
lance examinations within the indications, the shortest
timeframe scored as either uncertain or appropriate
marks the start of the period during which testing may
be considered reasonable. It is important that clinical
judgment be used during the period in which surveil-
lance is considered either uncertain or appropriate to
determine the optimal time of surveillance.
0. Unless explicitly stated, the indications in this docu-
ment indicate only whether vascular ultrasound or
physiological testing by itself is reasonable. The indi-
cations do not address whether it is reasonable to
perform vascular ultrasound or physiological testing
instead of or in conjunction with another test, either
before or after the test.
1. Surveillance indications require consideration of sev-
eral timeframes. Unlike other indications, the rater
should consider the comparative utility of surveillance
at the various frequencies specified.
2. New or worsening symptoms during a surveillance
period should be considered similar to the initial pre-
sentation and assumed to be covered by the earlier
relevant indications rather than the surveillance tables.
. DEFINITIONS
. Claudication:
Reproducible muscle discomfort or fatigue occurring
with exertion at the same workload and relieved with
rest, typically due to arterial obstruction.
. Cold extremity:
Reduced temperature from patient history or observed
on physical examination by physician.
. Physiological testing:
Evaluation of the peripheral circulation based on measure-
ment of limb blood pressures with pulse volume record-
ings or Doppler waveforms, or other parameters without
utilizing data from direct imaging of the blood vessels.
. Resistant hypertension:
The failure to normalize blood pressure on 3 or more
drug regimen with medications at maximum doses and
at least 1 of the medications being a diuretic agent.
. Malignant hypertension:
Uncontrolled hypertension causing acute heart failure,
acute renal failure, or acute visual or mental status
changes.
. Disease surveillance:
Baseline physiological testing or imaging:
Testing conducted for initial diagnosis or for initial clinical
evaluation post surgical or percutaneous intervention.
Surveillance:
Physiological testing or imaging conducted to monitor
disease progression based solely on the passage of time
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that baseline testing has already been conducted.
5. ABBREVIATIONS
ABI  ankle-brachial index
ACE  angiotensin-converting enzyme inhibitor
ARB  angiotensin II receptor blocker
CABG  coronary artery bypass graft PT  computed tomography
I  gastrointestinal
CA  internal carotid artery
CAVL  Intersocietal Commission for the Accreditation
f Vascular Laboratories
MT  intima-media thickness
AD  peripheral artery disease
VR  pulse volume recording
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CRITERIA (BY INDICATION)
Section 1. Extracranial Cerebrovascular Ultrasound
Table 1.1. Evaluation for Cerebrovascular Disease—Potential Signs and/or Symptoms
Indication
Appropriate Use
Score (1-9)
1. ● New or worsening hemispheric neurological symptoms (eg, unilateral motor or sensory deficit, speech
impairment, or amaurosis fugax)
● Evaluation of transient ischemic attack or stroke
A (9)
2. ● Hollenhorst plaque visualized on retinal examination A (8)
3. ● Lightheadedness or impaired vision in the setting of upper extremity exertion
● Evaluation for subclavian–vertebral steal phenomenon
A (7)
4. ● Syncope of uncertain cause after initial cardiovascular evaluation U (5)
5. ● Suspected symptomatic vertebrobasilar occlusive disease in the symptomatic patient (eg, vertigo,
ataxia, diplopia, dysphagia, dysarthria)
A (7)
6. ● Evaluation for suspected carotid artery dissection A (8)
7. ● Pulsatile neck mass A (8)
8. ● Cervical bruit
● No prior carotid artery assessment
A (7)
A  appropriate; I  inappropriate; U  uncertain.
Table 1.2. Evaluation for Cerebrovascular Disease—Asymptomatic With Comorbidities or Risk Factors for Carotid Artery
Stenosis
Indication
Appropriate Use
Score (1-9)
9. ● No cervical bruit
● Atherosclerotic disease in other vascular beds (eg, lower extremity PAD, coronary artery disease,
abdominal aortic aneurysm)
A (7)
10. ● No cervical bruit
● History of neck irradiation 10 years ago
U (5)
11. ● Known renal fibromuscular dysplasia U (5)
Prior to Open Heart Surgery
12. ● Planned coronary artery bypass grafting (CABG) U (6)
13. ● Atherosclerotic disease in other vascular beds (eg, lower extremity PAD, coronary artery disease,
abdominal aortic aneurysm), or history of neck irradiation 10 years ago
● Planned valve repair/replacement surgery (without CABG)
U (6)
14. ● Atherosclerotic risk factors present
● Planned valve repair/replacement surgery (without CABG)
U (6)
15. ● No atherosclerotic risk factors
● Planned valve repair/replacement surgery (without CABG)
U (4)
A  appropriate; CABG  coronary artery bypass graft; I  inappropriate; PAD  peripheral artery disease; U  uncertain.
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Indication Appropriate Use Score (1-9)
16. ● Normal prior examination (no plaque, no stenosis) I (1)
Surveillance Frequency During First Year At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
17. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity) I (1) I (1) I (1)
18. ● Mild ICA stenosis (eg, 50%) I (1) I (1) I (1)
19. ● Moderate ICA stenosis (eg, 50% to 69%) I (2) U (6) U (6)
20. ● Severe ICA stenosis (eg, 70% to 99%) U (5) A (7) U (6)
Surveillance Frequency After First Year Every 6
months
Every 12
months
Every 24
months or
greater
21. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity) I (1) I (3) I (1)
22. ● Mild ICA stenosis (eg, 50%) I (2) U (5) U (6)
23. ● Moderate ICA stenosis (eg, 50% to 69%) I (3) A (7) U (6)
24. ● Severe ICA stenosis (eg, 70% to 99%) A (7) A (7) U (6)
A  appropriate; I  inappropriate; ICA  internal carotid artery; U  uncertain.
*In the setting of interval development of clinical symptoms in a previously asymptomatic patient or for rapid progression of stenosis during subsequent
follow-up (eg, stenosis category change during a limited period of time), more intensive surveillance may be indicated.
†Carotid artery occlusion to be addressed in the text of the document. Periodic surveillance duplex ultrasound should be performed according to the severity
of stenosis of the contralateral side.Table 1.4. Surveillance After Carotid Artery Intervention
Indication Appropriate Use Score (1-9)
25. ● Baseline (within 1 month) after carotid intervention A (8)
Asymptomatic or Stable Symptoms After Baseline Study,
Surveillance Frequency During First Year
At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
26. ● Following normal ipsilateral ICA baseline study I (2) A (7) A (7)
27. ● Following abnormal ipsilateral ICA baseline study U (4) A (7) U (5)
Asymptomatic or Stable Symptoms After Baseline Study,
Surveillance Frequency After First Year
Every 6
months
Every 12
months
Every 24
months or
greater
28. ● Following normal ipsilateral ICA baseline study I (2) A (7) U (5)
29. ● Following abnormal ipsilateral ICA baseline study U (4) A (7) U (5)A  appropriate; I  inappropriate; ICA  internal carotid artery; U  uncertain.
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L 20Section 2. Carotid Duplex Screening Ultrasound
Summary: Extracranial Cerebrovascular and Carotid
Duplex Screening Ultrasound. There was significant
consensus regarding the appropriateness of cerebrovascular
duplex ultrasound for evaluation of the patient with signs
or clinical symptoms of cerebrovascular disease (Table 1.1)
with 7 of 8 clinical indications rated as appropriate and 1
clinical indication rated as uncertain.
Use of cerebrovascular ultrasound was rated as appro-
priate for evaluation of the patient with suspected vertebro-
basilar occlusive disease with posterior circulation symp-
toms; although a customized cerebrovascular scanning
protocol and supplemental use of transcranial Doppler may
be needed for complete assessment of such patients. The
multisocietal consensus guidelines for the management of
patients with extracranial carotid and vertebral artery dis-
ease recommend other imaging modalities (ie, magnetic
resonance angiogram or computed tomography angiogra-
phy) rather than ultrasound as the initial imaging test for
suspected vertebral artery stenosis.4 Though carotid ultra-
sound was rated as appropriated for evaluation of suspected
carotid artery dissection, its use is best suited for evaluation
of suspected carotid dissection arising from dissection of
the aortic arch and extending into the arch vessels (eg,
common carotid artery). Carotid ultrasound is not recom-
mended to diagnose carotid dissection in the setting of
trauma as a distal dissection of the internal carotid artery
may not be detected by duplex scanning. In such cases,
another other imaging modality (ie, MRA or CTA) should
be used.
Appropriateness of the use of cerebrovascular duplex ul-
trasound to assess for carotid stenosis in the patient with
syncope with no obvious cardiac cause was rated as uncertain
by the panel. Cerebrovascular disease is an unlikely cause of
syncope but has been reported in cases of severe (especially
bilateral) internal carotid artery stenosis or severe vertebro-
basilar occlusive disease or subclavian–vertebral artery steal.
Table 2.1. Limited Screening Study for Carotid Artery Pl
Indication
30. ● Low Framingham risk score
● No prior risk assessment imaging study, such as coronary
31. ● Intermediate Framingham risk score
● No prior risk assessment imaging study, such as coronary
32. ● Low or intermediate Framingham risk score
● Normal prior risk assessment imaging study, such as coro
33. ● High Framingham risk score
A  appropriate; I  inappropriate; IMT  intima-media thickness; U  u
*A screening carotid duplex examination includes assessment for the presenc
grey-scale imaging and assessment for stenosis of the proximal internal car
performed using a limited but clearly defined screening protocol (see ICAV
include formal measurement of carotid intimal medial thickness.The yield of cerebrovascular ultrasound in the evaluation of yyncope has been low in published case series, but the
ncertain rating for this indication reflects the need for
dditional research, including cost effectiveness data, in this
rea.5,6
In contrast to the evaluation of the symptomatic pa-
ient or patient with signs of cerebrovascular disease, there
as uncertainty regarding the use of cerebrovascular duplex
or assessment of the asymptomatic patient with risk factors
r comorbidities associated with carotid artery stenosis (Table
.2), with 6 of 7 indications receiving an uncertain rating
nd only 1 indication receiving an appropriate rating. The
echnical panel rated as uncertain all clinical scenarios for
erebrovascular duplex examination prior to cardiac sur-
ery, including evaluation of any asymptomatic patient (ie,
o prior hemispheric symptoms, no bruit) prior to CABG
nd evaluation of an asymptomatic patient prior to valvular
eart surgery, including patients with or without risk fac-
ors or comorbidities associated with cerebrovascular dis-
ase. These findings reflect a need for more research in this
rena, particularly cost effectiveness data.
Clinical management of the asymptomatic patient with
therosclerotic carotid disease typically includes periodic
ltrasound surveillance for progressive carotid artery steno-
is with the objective of referral for surgical (endarterec-
omy) or interventional (carotid artery stenting) therapy for
evere stenosis of the internal carotid artery.7 The technical
anel reviewed the appropriateness of time points for such
urveillance studies (Table 1.3) during the first year after
nitial diagnosis of carotid stenosis and during subsequent
ollow-up across all severity categories. Any follow-up was
eemed inappropriate following a normal baseline carotid
xamination (ie, absent plaque or narrowing). For surveil-
ance of the patient with plaque without narrowing noted
n initial duplex examination or mild stenosis of50%, any
urveillance during the first year of follow-up was also
eemed inappropriate, and surveillance beyond the first
—Asymptomatic*
Appropriate Use
Score (1-9)
m scoring or carotid IMT measurement
I (2)
m scoring or carotid IMT measurement
U (4)
calcium scoring or carotid IMT measurement
I (3)
U (5)
in.
therosclerotic plaque within the common and internal carotid arteries using
rtery using spectral Doppler. The screening carotid duplex examination is
10 standards 5.1.5).3 A screening study for carotid artery plaque does notaque
calciu
calciu
nary
ncerta
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otid aear was uncertain. Ratings for time points for surveillance
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likely reflect the lack of substantial clinical effectiveness data
in this arena, with the majority of indications rated as
uncertain. For moderate ICA lesions, repeat ultrasound
studies within the first year after diagnosis were rated as
inappropriate (at 3 to 5 months) or uncertain, with annual
studies rated as appropriate. For severe ICA lesions, an
ultrasound study at 6 months and then every 6 or 12
months were rated as appropriate, although it should be
emphasized that at this severity of stenosis, the risks versus
benefits of revascularization (carotid artery endarterectomy
or stenting) should be considered.7
The panel reviewed indications for cerebrovascular du-
plex ultrasound after carotid artery revascularization (end-
arterectomy or stenting). Obtaining a baseline bilateral
cerebrovascular duplex examination was highly rated as
appropriate by the technical panel. The panel rated indica-
tions for follow-up during the first year after revasculariza-
tion and beyond based upon whether the initial postrevas-
cularization duplex demonstrated normal, expected
postprocedural findings, or indicated a postprocedural abnor-
mality (eg, significantly elevated velocities) in Table 1.4.
Though not included in the rated clinical indications, it is
likely that frequency and appropriateness of testing intervals
would change in the setting of new abnormalities identified onCT  computed tomography; I  inappropriate; U  uncertain.estenosis or significant restenosis at a carotid endarterectomy
ite.
The presence of carotid artery plaque with or without
tenosis has been associated with increased cardiovascular
isk in epidemiological studies, including increased risk of
yocardial infarction.8-11 The technical panel reviewed the
ppropriateness of a carotid duplex screening ultrasound
xamination to screen plaque and significant narrowing of
he proximal internal carotid arteries. However, these rat-
ngs do not include the appropriateness of carotid intima-
edial thickness (IMT) assessment, a procedure that re-
uires additional technological capabilities and is not
idely nor routinely performed in the clinical vascular
aboratory setting. The technical panel rated 2 indications
s inappropriate for carotid screening ultrasound: assess-
ent of the patient with low Framingham risk score and
ssessment of the patient with low or intermediate Fra-
ingham risk score who has already undergone another
maging risk assessment (eg, carotid IMT or coronary
rtery calcium scoring). The technical panel rated assess-
ent of the patient with intermediate or high Framing-
am risk score and without prior imaging risk assessment
tudy as uncertain indications for carotid ultrasound,
eflecting again the need for outcome and clinical effec-a surveillance duplex examination, such as significant in-stent tiveness data for these screening indications.
Section 3. Renal and Mesenteric Artery Duplex
Table 3.1. Evaluation for Renal Artery Stenosis—Potential Signs and/or Symptoms
Indication
Appropriate Use
Score (1-9)
Creatinine Elevation and/or Hypertension
34. ● Malignant hypertension (see Assumptions) A (8)
35. ● Resistant hypertension (see Assumptions) A (8)
36. ● Worsening blood pressure control in long-standing hypertensive patient A (8)
37. ● Hypertension in young person (age 35 years) A (8)
38. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension) A (7)
39. ● Unknown cause of azotemia (eg, unexplained increase in creatinine) A (7)
40. ● Increased creatinine (50% baseline or above normal levels) after the administration of ACE/ARBs A (8)
41. ● Acute renal failure with aortic dissection A (8)
42. ● Epigastric bruit A (7)
Heart Failure of Unknown Origin
43. ● Refractory CHF A (7)
44. ● “Flash” pulmonary edema A (8)
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; CHF  congestive heart failure.
Table 3.2. Screening for Renal Artery Stenosis—Asymptomatic
Indication
Appropriate Use
Score (1-9)
45. ● Atherosclerotic vascular disease in other beds (eg, peripheral artery disease) and well-controlled
hypertension
I (3)
46. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension)as discovered
by CT or ultrasound
U (4)
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sound. In this section, the ratings were found to be appro-
priate for the hypertension, creatinine, and heart failure
indications in evaluating for renal artery stenosis. The only
appropriate indication for duplex investigation of mesen-
teric artery stenosis was for the patients with symptoms of
postprandial pain and weight loss and who have undergone
Table 3.3. Evaluation for Mesenteric Artery Stenosis—Po
Indication
Sym
47. ● Evaluate for acute abdominal pain “out of proportion to
● Leukocytosis, “thumbprinting,” pneumatosis or hemoco
amylase, alkaline phosphatase, or CPK
48. ● Postprandial pain or weight loss not otherwise explained
● GI evaluation previously completed
49. ● Postprandial pain or discomfort
● GI evaluation not yet undertaken
50. ● Chronic constipation or diarrhea
● GI evaluation not yet undertaken
51. ● Unexplained or unintended weight loss
52. ● Abdominal or epigastric bruit
A  appropriate; CPK  creatine phosphokinase; GI  gastrointestinal; I 
Table 3.4. Follow–Up Testing for Renal Artery Stenosis—
Indication
53. ● Prior imaging indicates r
● Determine hemodynami
54. ● Surveillance of known re
A  appropriate; U  uncertain.
Table 3.5. Surveillance After Renal or Mesenteric Artery R
Indication
Asym
55. ● Baseline surveillance (within 1 month) after revascu
New or Worsening S
56. ● After renal or mesenteric artery revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Su
Frequency During First Year
57. ● During first 12 months after endovascular revascul
Asymptomatic or Stable Symptoms After Baseline Study, Su
Frequency After First Year
58. ● After first 12 months after endovascular revasculari
A  appropriate; I  inappropriate; U  uncertain.esenteric artery revascularization was deemed to be ap-
ropriate at 1 month following the procedure to establish a
aseline and any time there are new signs or symptoms.
urveillance every 12 months was the only follow-up time
rame rated appropriate after endovascular and surgical
evascularization. Routine surveillance following surgical
enal or mesenteric revascularization is generally not re-
al Signs and/or Symptoms
Appropriate
Use Score (1-9)
atic
”
tration, and acidosis with or without elevated
I (3)
A (8)
U (5)
I (3)
U (5)
U (4)
propriate; U  uncertain.
mptomatic
Appropriate
Use Score (1-9)
artery stenosis
ificance
A (7)
tery stenosis U (6)
scularization
Appropriate Use Score (1-9)
atic
ation A (8)
toms After Baseline
A (8)
ance At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
ion I (3) U (6) U (6)
ance Every 6
months
Every 12
months
Every 24
months or
greater
n I (3) A (7) U (5)a gastrointestinal (GI) evaluation. Surveillance after renal or quired in the absence of recurrent or worsening symptoms.tenti
ptom
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Table 4.1. Evaluation for Abdominal Aortic Disease—Sig
Indication
59. ● Lower extremity claudication
60. ● Nonspecific lower extremity discomfort
61. ● New onset abdominal or back pain
62. ● Aneurysmal femoral or popliteal pulse
63. ● Pulsatile abdominal mass
64. ● Decreased or absent femoral pulse
65. ● Abdominal or femoral bruit
66. ● Fever of unknown origin
67. ● Lower extremity swelling
68. ● Evidence of atheroemboli in the lower e
69. ● Erectile dysfunction
70. ● Abnormal physiologic testing indicating
71. ● Hypertension
72. ● Abnormal abdominal x-ray suggestive of
73. ● Presence of a lower extremity arterial ane
74. ● Presence of a thoracic aortic aneurysm
A  appropriate; I  inappropriate; U  uncertain.
Table 4.2. Screening for Abdominal Aortic Aneurysm—A
Indication
75. ● Men age 60 years
● First degree relative with an ab
76. ● Women age 60 years
● First degree relative with an ab
77. ● Men age 65 to 75 years
● Current or former smoker
78. ● Women age 65 to 75 years
● Current or former smoker
79. ● Age 75 years
● Current or former smoker
80. ● Age 65 years
● No history of smoking
81. ● Age 65 years
● No history of smoking
A  appropriate; I  inappropriate; U  uncertain.ns and/or Symptoms
Appropriate Use
Score (1-9)
A (7)
I (3)
U (6)
A (8)
A (9)
A (7)
A (7)
I (3)
I (2)
xtremities, including ischemic toes A (8)
U (4)
aortoiliac occlusive disease A (8)
I (3)
aneurysm A (8)
urysm (eg, femoral or popliteal) A (8)
A (8)symptomatic
Appropriate Use
Score (1-9)
dominal aortic aneurysm
A (8)
dominal aortic aneurysm
A (8)
A (8)
A (7)
A (7)
U (5)
I (3)
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Indication Appropriate Use Score (1-9)
New or Worsening Symptoms
82. ● Known abdominal aortic aneurysm (any size) A (9)
Asymptomatic or Stable Symptoms After Baseline Study,
Surveillance Frequency During First Year
At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter I (1) U (4) A (7)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter I (1) U (4) A (7)
85. ● Aneurysm 4.0 to 5.4 cm in diameter U (4) A (7) A (7)
86. ● Aneurysm 5.5 cm in diameter A (7) A (7) U (6)
Asymptomatic or Stable Symptoms, No or Slow Progression
During First Year, Surveillance Frequency After First Year
Every 6
months
Every 12
months
Every 24
months or
greater
87. ● Men, aneurysm 3.0 to 3.9 cm in diameter I (2) A (7) A (7)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter I (2) A (7) A (7)
89. ● Aneurysm 4.0 to 5.4 cm in diameter U (5) A (7) U (6)
90. ● Aneurysm 5.5 cm in diameter A (8) A (7) U (5)
Asymptomatic or Stable Symptoms, Rapid Progression
During First Year, Surveillance Frequency After First Year
Every 6
months
Every 12
months
Every 24
months or
greater
91. ● Men, aneurysm 3.0 to 3.9 cm in diameter A (7) A (7) U (4)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter A (8) A (7) U (4)
93. ● Aneurysm 4.0 to 5.4 cm in diameter A (8) A (7) U (4)
94. ● Aneurysm 5.5 cm in diameter A (9) U (5) I (3)A  appropriate; I  inappropriate; U  uncertain.Table 4.4. Surveillance After Aortic Endograft or Aortoiliac Stenting
Indication Appropriate Use Score (1-9)
Baseline (Within 1 Month After the Intervention)
95. ● Aortic or iliac endograft A (8)
96. ● Aortic and iliac artery stents A (7)
New or Worsening Lower Extremity Symptoms After Baseline Exam
97. ● Aortic or iliac endograft A (8)
98. ● Aortic and iliac artery stents A (8)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance
Frequency During First Year
At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
99. ● Aortic endograft without endoleak stable and/or decreasing residual
aneurysm sac size
I (3) U (5) U (6)
100. ● Aortic endograft with endoleak and/or increasing residual aneurysm
sac size
U (6) A (8) A (7)
101. ● Aortic or iliac artery stents I (2) U (5) U (6)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance
Frequency After First Year
Every 6
months
Every 12
months
Every 24
months or
greater
102. ● Aortic endograft without endoleak stable and/or decreasing residual
aneurysm sac size
I (3) A (7) U (5)
103. ● Aortic endograft with endoleak and/or increasing residual aneurysm
sac size
A (8) A (7) U (5)
104. ● Aortic or iliac artery stents I (2) U (5) U (5)A  appropriate; I  inappropriate; U  uncertain.
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Signs and symptoms considered as appropriate indications
for duplex evaluation of the abdominal aorta and iliac
arteries included intermittent claudication, an aneurysmal
femoral or popliteal pulse, a pulsatile abdominal mass, a
decreased or absent femoral pulse, and an abdominal or
femoral bruit. Inappropriate indications included nonspe-
cific lower extremity discomfort, fever of unknown origin,
lower extremity swelling, and hypertension. Erectile dys-
function was the only indication rated as uncertain.
Ultrasound screening of asymptomatic individuals for ab-
dominal aortic aneurysms was considered appropriate in men
and women over age 60 who were known to have first-degree
relatives with an abdominal aortic aneurysm. Screening was
also appropriate for men and women between 65 and 75 years
of age who were current or former smokers and any current or
former smoker over age 75. However, ultrasound screening
was inappropriate for individuals under age 65 with no history of
smoking. There was uncertainty over the role of screening for
those age 65 and older with no history of smoking.
The reviewers concurred with the primary recommen-
dation of the U.S. Preventive Services Task Force (USP-
STF) that screening for abdominal aortic aneurysms was
appropriate for men aged 65 to 75 years who had ever
smoked.12 However, the reviewers also considered screen-
ing appropriate in both men and women who had a first-
degree relative with an abdominal aortic aneurysm, a situ-
ation that was acknowledged in the USPSTF report by
stating that “clinicians must individualize recommenda-
tions depending on a patient’s risk and likelihood of bene-
fit.” Although the reviewers rated aneurysm screening as
appropriate in women aged 65 to 75 years who were
current or former smokers, the USPSTF recommended
against routine screening in women, based on the low
prevalence of large abdominal aortic aneurysms and con-
cern that the harms of screening outweighed the benefits.
The reviewers also considered screening appropriate for
patients over 75 years of age who were current or former
smokers, even though the USPSTF set an upper age limit
for screening of 75 years, since the increased prevalence of
comorbidities would decrease the chances that older patients
would benefit from screening. It is important to note that the
purposeof theUSPSTFrecommendationsdiffer fromthatof this
AUC document. The USPSTF provides guidance on whether
population-based screening is generally recommended whereas
AUC look at how reasonable testing may be for specific patient
populations.
The reviewers’ ratings were generally consistent with
recommendations for aneurysm screening from the Society
for Vascular Surgery (SVS) and the American College of
Cardiology (ACC)/American Heart Association (AHA)
2005 Practice Guidelines.13,14 The SVS recommends
1-time ultrasound screening for all men at age 65 or older,
or at age 55 or older for men with a positive family history
for abdominal aortic aneurysms. For women, the SVS
recommends screening at age 65 or older if they have ever
smoked or have a positive family history. The ACC/AHA
guidelines recommend aneurysm screening for high-risk sopulations, defined as men 60 years of age or older with
rst-degree relatives who have abdominal aortic aneurysms
nd men 65 to 75 years of age who have ever smoked.
For surveillance of a known abdominal aortic aneurysm
f any size, duplex ultrasound was rated as appropriate.
hen patients who were asymptomatic or had stable symp-
oms were considered according to aneurysm size and
urveillance frequency, follow-up at 9 to 12 months after a
aseline study was rated as appropriate for aneurysms 3.0
m to 3.9 cm in diameter in both men and women. Earlier
ollow up at 3 to 5 months after a baseline study was
nappropriate, and the value of follow-up at 6 to 8 months
as uncertain. After the first year, follow-up was rated as
ppropriate for aneurysms 3.0 cm to 3.9 cm in diameter at
ither 12-month or 24-month intervals for those patients
ith no or slow progression during the first year.
For patients with aneurysms of 4.0 cm to 5.4 cm,
urveillance at intervals of 6 to 8 months or 9 to 12 months
fter a baseline study was appropriate. Surveillance for
neurysms of 5.5 cm or more in diameter was appropriate at
to 5 months and 6 to 8 months in the first year and
ntervals of 6 months and 12 months after the first year,
ssuming no or slow progression. When rapid progression
as observed on serial studies, follow-up was appropriate at
-month and 12-month intervals for aneurysms 3.0 cm to
.9 cm in diameter and those 4.0 cm to 5.4 cm in diameter.
owever, for aneurysms of 5.5 cm or more in diameter
ith rapid progression, follow up was rated as appropriate
nly at 6-month intervals, whereas the value of follow-up at
2-month intervals was uncertain, and follow-up at 24-
onth intervals was inappropriate. Since patients with an-
urysms of 5.5 cm or more in diameter are usually consid-
red for elective repair, the role of continued surveillance
ust be individualized. If a patient has reversible or time-
imited factors that prevent elective aneurysm repair, then
ngoing surveillance may play a role in clinical decision
aking. However, if a patient declines elective repair, or is
ot considered a candidate for repair under any circum-
tances, then the value of surveillance is questionable.
After an aortic endograft or aortoiliac stenting, duplex
canning was appropriate as a baseline study (within 1
onth), as well as for any subsequent new or worsening
ower extremity symptoms. For aortic endograft patients
ith stable or decreasing residual aneurysm sac size and
ithout evidence of endoleak during the first year, duplex
ollow-up was rated as inappropriate at 3to 5 months and
ncertain at both 6 to 8 months and 9 to 12 months.
owever, in the presence of an endoleak or increasing
esidual aneurysm sac size during the first year, follow-up
as considered appropriate at either at 6 to 8 months or 9
o 12 months. For asymptomatic patients and those with
table symptoms during the first year after aortic or iliac
rtery stenting, duplex follow-up was rated as inappropriate
t 3 to 5 months and uncertain at 6 to 8 months and 9 to 12
onths. Similarly, follow-up every 6 months or 12 months
as inappropriate and follow-up every 24 months or
reater was considered as uncertain for aortic or iliac artery
tent patients who were asymptomatic or had stable symp-
1
i
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without evidence of endoleak and stable or decreasing2-month intervals. When there was an endoleak or increas-
ng residual aneurysm sac size after the first year, follow-up wasresidual aneurysm sac size after the first year was appropriate at appropriate at either 6-month or 12-month intervals.
Section 5. Lower Extremity Artery Testing Using Multilevel Physiological Testing Alone
or Duplex Ultrasound With Single-Level ABI and PVR
Table 5.1. Evaluation for Lower Extremity Atherosclerotic Disease—Potential Signs and/or Symptoms
Indication
Appropriate Use
Score (1-9)
105. ● Lower extremity claudication A (9)
106. ● Leg/foot/toe pain at rest A (9)
107. ● Foot or toe ulcer or gangrene A (9)
108. ● Infection of leg/foot without palpable pulses A (9)
109. ● Suspected acute limb ischemia (eg, cold, painful limb with pallor, pulselessness, parasthesias) A (9)
110. ● Nocturnal leg cramps
● Normal pulses
I (2)
111. ● Lack of hair growth on dorsum of foot or toes
● Normal pulses
I (2)
112. ● Evidence of atheroemboli in the lower extremities A (8)
113. ● Lower extremity swelling
● Normal pulses
I (2)
114. ● Diabetes with peripheral neuropathy
● Normal pulses
I (3)
A  appropriate; I  inappropriate.
Table 5.2. Surveillance of Known Lower Extremity PAD
Indication Appropriate Use Score (1-9)
New or Worsening Symptoms
115. ● Normal baseline study A (7)
116. ● Abnormal baseline ABI (ie, ABI 0.90) A (8)
No Change in Symptom Status (No revascularization)
Asymptomatic or Stable Symptoms After Baseline Study,
Surveillance Frequency During First Year
At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
117. ● Normal baseline ABI (no stenosis) I (1) I (1) I (1)
118. ● Mild or moderate disease (eg, ABI 0.4) I (2) I (2) U (4)
119. ● Severe (eg, ABI 0.4) I (3) U (5) U (5)
Asymptomatic or Stable Symptoms After Baseline Study,
Surveillance Frequency After First Year
Every 6
months
Every 12
months
Every 24
months or
greater
120. ● Normal baseline ABI (no stenosis) I (1) I (1) I (2)
121. ● Mild or moderate disease (eg, ABI 0.4) I (2) I (2) U (4)
122. ● Severe (eg, ABI 0.4) U (4) U (4) I (3)
A  appropriate; ABI  ankle-brachial index; I  inappropriate; PAD  peripheral artery disease; U  uncertain.
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Table 5.3. Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
Indication Appropriate Use Score (1-9)
123. ● Baseline surveillance (within 1 month) A (8)
New or Worsening Symptoms
124. ● After revascularization (angioplasty  stent or bypass) A (9)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study,
Surveillance Frequency During First Year
At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
125. ● After angioplasty  stent placement I (2) U (6) U (6)
126. ● After vein bypass graft U (6) A (8) U (6)
127. ● After prosthetic bypass graft U (5) A (7) U (5)
Asymptomatic or Stable Symptoms After Baseline Study,
Surveillance Frequency After First Year
Every 6
months
Every 12
months
Every 24 months
or greater
128. ● After angioplasty  stent placement I (3) A (7) U (5)
129. ● After vein bypass graft U (5) A (7) U (5)
130. ● After prosthetic bypass graft I (3) A (7) U (5)
A  appropriate; I  inappropriate; PAD  peripheral artery disease; U  uncertain.
Table 6.1. Screening for Lower Extremity Atherosclerotic Disease—Potential Signs
Indication
Appropriate Use
Score (1-9)
131. ● Diminished pulses A (7)
132. ● Femoral bruit A (7)
A  appropriate.
Table 6.2. Screening for Lower Extremity Atherosclerotic Disease—Asymptomatic With Comorbidities
Indication
Appropriate Use
Score (1-9)
133. ● Age 50 years
● With diabetes
A (7)
134. ● Age 50 years
● With diabetes
U (5)
135. ● Age 50 years
● Cigarette smoking (current or past)
A (7)
136. ● Age 70 years A (7)
A  appropriate; U  uncertain.
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Section 8. Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Table 7.1. Evaluation for Groin Complication After Femoral Access
Indication
Appropriate Use
Score (1-9)
137. ● Pulsatile groin mass A (9)
138. ● Bruit or thrill over the groin A (8)
139. ● Ecchymosis U (4)
140. ● Significant hematoma A (7)
141. ● Severe pain within groin post procedure A (7)
A  appropriate; U  uncertain.
Table 8.1. Evaluation for Upper Extremity PAD—Potential Signs and/or Symptoms
Indication
Appropriate Use
Score (1-9)
142. ● Arm or hand claudication A (8)
143. ● Finger discoloration or ulcer A (8)
144. ● Unilateral cold painful hand A (8)
145. ● Raynaud’s phenomenon U (5)
146. ● Suspected positional arterial obstruction (eg, thoracic outlet syndrome) A (7)
147. ● Upper extremity trauma with suspicion of vascular injury A (8)
148. ●Discrepancy in arm pulses or blood pressure discrepancy of20 mm Hg between arms U (6)
149. ● Periclavicular bruit U (5)
150. ● Pre-op radial artery harvest (eg, for CABG) A (7)
151. ● Presence of pulsatile mass or hand ischemia after upper extremity vascular access A (8)
152. ● Presence of bruit after upper extremity access for intervention A (8)
A  appropriate; CABG  coronary artery bypass graft; PAD  peripheral artery disease; U  uncertain.
Table 8.2. Surveillance of Upper Extremity PAD After Revascularization
Indication Appropriate Use Score (1-9)
153. ● Baseline (within 1 month) A (8)
New or Worsening Symptoms
154. ● After revascularization (stent or bypass) A (8)
155. ● Post trauma A (8)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During
First Year
At 3 to 5
months
At 6 to 8
months
At 9 to 12
months
156. ● After vein bypass graft U (6) A (7) U (5)
157. ● After prosthetic bypass graft I (3) U (6) U (4)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After
First Year
Every 6
months
Every 12
months
Every 24
months or
greater
158. ● After vein bypass graft U (4) A (7) U (5)
159. ● After prosthetic bypass graft U (4) A (7) U (4)
A  appropriate; I  inappropriate; PAD  peripheral artery disease; U  uncertain.
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Testing. The screening of asymptomatic individuals with
ABI alone in this document is also addressed by the USP-
STF. The rating of “uncertain” in this document is not
consistent with that of the USPSTF where this type of
evaluation was not deemed appropriate, or level D. There
have been published responses to the USPSTF stance
pointing out that ABI evaluation of certain populations
would identify a high-risk group for heart attack, stroke,
and death.15 The ACC/AHA guidelines and the American
Diabetes Association Guidelines advocate ABI testing in
certain disease populations such as those age 50 years
with diabetes or chronic smoking. The designation of “un-
certain” in this document is reflective of a paucity of data
regarding ABI evaluation alone in asymptomatic individu-
als and effect on prevention of claudication and limb loss.
The designation of “uncertain” is not meant to address the
potential impact of ABI evaluation on heart attack and
stroke outcome. The AUC ratings are meant to determine
when diagnostic testing may be a reasonable option under
certain clinical circumstances. They are not intended to
endorse or imply population-wide screening protocols that
are the focus of the USPSTF.
Theappropriate indications for lower extremity testingusing
multilevel physiological methods alone or duplex ultrasound
with single-level ABI and pulse volume recording (PVR) were
clearly delineated by the reviewers with 6 appropriate and 4
inappropriate. None of the indications were deemed uncertain.
Nocturnal leg cramps, neuropathy, lower extremity swelling or
hair loss in the setting of normal pulses are not clinical scenarios
that support ordering lower extremity artery tests.
There are 2 clear appropriate indications for surveil-
lance of known lower extremity arterial disease, patients
with either a normal ABI or an abnormal ABI with new or
worsening symptoms. A short follow-up interval of every 6
months is not indicated, whereas it was uncertain whether mvery 12 months or every 24 months or greater was appropri-
te for follow-up testing. A baseline study after lower extrem-
ty revascularization was deemed appropriate, as was testing
or new or worsening symptoms after revascularization. A
ollow-up interval for surveillance after baseline evaluation was
hought most appropriate at 12 months if the patient is stable
ithout new or worsening symptoms. The most appropriate
ime for surveillance after lower extremity prosthetic or vein
ypass graft was 6to 8 months after the procedure.
Theappropriate indications for lowerextremityartery testing
ith ABI only were diminished pulses, femoral bruit, age 50
ears with diabetes or smoking, and age 70 years, which is
onsistent with ACC/AHA peripheral artery disease (PAD)
uidelines.TheevaluationwithABIonly for those age50years
ith diabetes was uncertain.
Theappropriate indications for lowerextremityduplexultra-
ound evaluation only included a pulsatile groin mass, bruit or
hrill, significant hematoma, or groin pain postprocedure. The
resence of ecchymosis only was an uncertain indication.
The appropriate indications for upper extremity arterial
esting included claudication, ulcer, unilateral cold painful
and, suspected positional arterial obstruction, and trauma
ith suspicion of vascular injury. The presence of Ray-
aud’s phenomenon was an uncertain indication. A preop-
rative evaluation for a procedure such as radial artery
arvest or suspected complication after an upper extremity
rterial intervention was also appropriate indications for
esting.
Similar to the lower extremity, a baseline study after
evascularization and new or worsening symptoms are ap-
ropriate indications for upper extremity arterial testing.
he most appropriate initial surveillance time interval after
pper extremity revascularization with either vein or pros-
hetic bypass graft was at 12 months. A surveillance period
f every 6 months after initial postoperative evaluation was
ost inappropriate for asymptomatic patients.
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CRITERIA (BY RATING)
Table 9. Appropriate Indications (Median Rating 7-9)
Indication
Appropriate Use
Score (1-9)
Extracranial Cerebrovascular Ultrasound
Evaluation for Cerebrovascular Disease—Potential Signs and/or Symptoms
1. ● New or worsening hemispheric neurological symptoms (eg, unilateral motor or sensory deficit, speech
impairment, or amaurosis fugax)
● Evaluation of transient ischemic attack or stroke
A (9)
2. ● Hollenhorst plaque visualized on retinal examination A (8)
3. ● Lightheadedness or impaired vision in the setting of upper extremity exertion
● Evaluation for subclavian-vertebral steal phenomenon
A (7)
5. ● Suspected symptomatic vertebrobasilar occlusive disease in the symptomatic patient (eg, vertigo, ataxia,
diplopia, dysphagia, dysarthria)
A (7)
6. ● Evaluation for suspected carotid artery dissection A (8)
7. ● Pulsatile neck mass A (8)
8. ● Cervical bruit
● No prior carotid artery assessment
A (7)
Evaluation for Cerebrovascular Disease—Asymptomatic With Comorbidities or Risk
Factors for Carotid Artery Stenosis
9. ● No cervical bruit
● Atherosclerotic disease in other vascular beds (eg, lower extremity PAD, coronary artery disease, abdominal
aortic aneurysm)
A (7)
Follow-up or Surveillance for Carotid Artery Stenosis—Asymptomatic*†
Surveillance Frequency During First Year
20. ● Severe ICA stenosis (eg, 70% to 99%)
● At 6 to 8 months
A (7)
Surveillance Frequency After First Year
23. ● Moderate ICA stenosis (eg, 50% to 69%)
● Every 12 months
A (7)
24. ● Severe ICA stenosis (eg, 70% to 99%)
● Every 6 months
A (7)
24. ● Severe ICA stenosis (eg, 70% to 99%)
● Every 12 months
A (7)
Surveillance After Carotid Artery Intervention
Surveillance Frequency During First Year
25. ● Baseline (within 1 month) after carotid intervention A (8)
26. ● Following normal ipsilateral ICA baseline study
● Surveillance at 6 to 8 months
A (7)
26. ● Following normal ipsilateral ICA baseline study
● Surveillance at 9 to 12 months
A (7)
27. ● Following abnormal ipsilateral ICA baseline study
● Surveillance at 6 to 8 months
A (7)
Surveillance Frequency After First Year
28. ● Following normal ipsilateral ICA baseline study
● Surveillance every 12 months
A (7)
29. ● Following abnormal ipsilateral ICA baseline study
● Surveillance every 12 months
A (7)
Renal and Mesenteric Artery Duplex
Evaluation for Renal Artery Stenosis—Potential Signs and/or Symptoms
Creatinine Elevation and/or Hypertension
34. ● Malignant hypertension (160/80 mm Hg) A (8)
35. ● Resistant hypertension (140/90 mm Hg on 3 meds) A (8)
36. ● Worsening blood pressure control in long-standing hypertensive patient A (8)
37. ● Hypertension in young person (age 35 years) A (8)
38. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension) A (7)
39. ● Unknown cause of azotemia (eg, unexplained increase in creatinine) A (7)
40. ● Increased creatinine (50% baseline or above normal levels) after the administration of ACE/ARBs A (8)
41. ● Acute renal failure with aortic dissection A (8)
42. ● Epigastric bruit A (7)
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Indication
Appropriate Use
Score (1-9)
Heart Failure of Unknown Origin
43. ● Refractory heart failure A (7)
44. ● “Flash” pulmonary edema A (8)
Evaluation for Mesenteric Artery Stenosis—Potential Signs and/or Symptoms
Symptomatic
48. ● Post prandial pain or weight loss not otherwise explained
● GI evaluation previously completed
A (8)
Follow-up Testing for Renal Artery Stenosis—Asymptomatic
53. ● Prior imaging indicates renal artery stenosis
● Determine hemodynamic significance
A (7)
Surveillance After Renal or Mesenteric Artery Revascularization
Asymptomatic
55. ● Baseline surveillance (within 1 month) after revascularization A (8)
New or Worsening Symptoms After Baseline
56. ● After renal or mesenteric artery revascularization A (8)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
58. ● After first 12 months after endovascular revascularization
● Surveillance every 12 months
A (7)
Aortic and Aortoiliac Duplex
Evaluation for Abdominal Aortic Disease—Signs and/or Symptoms
59. ● Lower extremity claudication A (7)
62. ● Aneurysmal femoral or popliteal pulse A (8)
63. ● Pulsatile abdominal mass A (9)
64. ● Decreased or absent femoral pulse A (7)
65. ● Abdominal or femoral bruit A (7)
68. ● Evidence of atheroemboli in the lower extremities, including ischemic toes A (8)
70. ● Abnormal physiologic testing indicating aortoiliac occlusive disease A (8)
72. ● Abnormal abdominal x-ray suggestive of aneurysm A (8)
73. ● Presence of a lower extremity arterial aneurysm (eg, femoral or popliteal) A (8)
74. ● Presence of a thoracic aortic aneurysm A (8)
Screening for Abdominal Aortic Aneurysm—Asymptomatic
75. ● Men age 60 years
● First degree relative with an abdominal aortic aneurysm
A (8)
76. ● Women age 60 years
● First degree relative with an abdominal aortic aneurysm
A (8)
77. ● Men age 65 to 75 years
● Current or former smoker
A (8)
78. ● Women age 65 to 75 years
● Current or former smoker
A (7)
79. ● Age 75 years
● Current or former smoker
A (7)
Surveillance of Known Abdominal Aortic Aneurysm
New or Worsening Symptoms
82. ● Known abdominal aortic aneurysm (any size) A (9)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 9 to 12 months
A (7)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 9 to 12 months
A (7)
85. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance at 6 to 8 months
A (7)
85. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance at 9 to 12 months
A (7)
86. ● Aneurysm 5.5 cm in diameter
● Surveillance at 3 to 5 months
A (7)
86. ● Aneurysm 5.5 cm in diameter
● Surveillance at 6 to 8 months
A (7)
Asymptomatic or Stable Symptoms, No or Slow Progression During First Year, Surveillance Frequency After First Year
87. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
87. ● Men, aneurysm 3.0 to 3.9 cm in diameter A (7)
● Surveillance every 24 months or greater
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Indication
Appropriate Use
Score (1-9)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 24 months or greater
A (7)
89. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 12 months
A (7)
90. ● Aneurysm 5.5 cm in diameter
● Surveillance every 6 months
A (8)
90. ● Aneurysm 5.5 cm in diameter
● Surveillance every 12 months
A (7)
Asymptomatic or Stable Symptoms, Rapid Progression During First Year, Surveillance Frequency After First Year
91. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
A (7)
91. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
A (8)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 12 months
A (7)
93. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 6 months
A (8)
93. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 12 months
A (7)
94. ● Aneurysm 5.5 cm in diameter
● Surveillance every 6 months
A (9)
Surveillance After Aortic Endograft or Aortoiliac Stenting
Baseline (Within 1 Month After the Intervention)
95. ● Aortic or iliac endograft A (8)
96. ● Aortic and iliac artery stents A (7)
New or Worsening Lower Extremity Symptoms After Baseline Exam
97. ● Aortic or iliac endograft A (8)
98. ● Aortic and iliac artery stents A (8)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
100. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance at 6 to 8 months
A (8)
100. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance at 9 to 12 months
A (7)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
102. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance every 12 months
A (7)
103. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance every 6 months
A (8)
103. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance every 12 months
A (7)
Lower Extremity Artery Testing Using Multilevel Physiological Testing Alone or Duplex Ultrasound With Single Level ABI
and PVR Evaluation for Lower Extremity Atherosclerotic Disease—Potential Signs and/or Symptoms
105. ● Lower extremity claudication A (9)
106. ● Leg/foot/toe pain at rest A (9)
107. ● Foot or toe ulcer or gangrene A (9)
108. ● Infection of leg/foot without palpable pulses A (9)
109. ● Suspected acute limb ischemia (eg, cold, painful limb with pallor, pulselessness, parasthesias) A (9)
112. ● Evidence of atheroemboli in the lower extremities A (8)
Surveillance of Known Lower Extremity PAD
New or Worsening Symptoms
115. ● Normal baseline study A (7)
116. ● Abnormal baseline ABI (ie, ABI 0.90) A (8)
Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
123. ● Baseline Surveillance (within 1 month) A (8)
New or Worsening Symptoms
124. ● After revascularization (angioplasty  stent or bypass) A (9)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
126. ● After vein bypass graft A (8)
● Surveillance at 6 to 8 months
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Indication
Appropriate Use
Score (1-9)
127. ● After prosthetic bypass graft
● Surveillance at 6 to 8 months
A (7)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
128. ● After angioplasty  stent placement
● Surveillance every 12 months
A (7)
129. ● After vein bypass graft
● Surveillance every 12 months
A (7)
130. ● After prosthetic bypass graft
● Surveillance every 12 months
A (7)
Lower Extremity Artery Testing With ABI Only
Screening for Lower Extremity Atherosclerotic Disease—Potential Signs
131. ● Diminished pulses A (7)
132. ● Femoral bruit A (7)
Lower Extremity Artery Testing With ABI Only
Screening for Lower Extremity Atherosclerotic Disease—Asymptomatic With Comorbidities
133. ● Age 50 years
● With diabetes
A (7)
135. ● Age 50 years
● Cigarette smoking (current or past)
A (7)
136. ● Age 70 years A (7)
Lower Extremity Artery Testing With Duplex Ultrasound Only
Evaluation for Groin Complication After Femoral Access
137. ● Pulsatile groin mass A (9)
138. ● Bruit or thrill over the groin A (8)
140. ● Significant hematoma A (7)
141. ● Severe pain within groin post procedure A (7)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Evaluation for Upper Extremity PAD—Potential Signs and/or Symptoms
142. ● Arm or hand claudication A (8)
143. ● Finger discoloration or ulcer A (8)
144. ● Unilateral cold painful hand A (8)
146. ● Suspected positional arterial obstruction (eg, thoracic outlet syndrome) A (7)
147. ● Upper extremity trauma with suspicion of vascular injury A (8)
150. ● Pre-op radial artery harvest (eg, for CABG) A (7)
151. ●Presence of pulsatile mass or hand ischemia after upper extremity vascular access A (8)
152. ● Presence of bruit after upper extremity access for intervention A (8)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Surveillance of Upper Extremity PAD After Revascularization
153. Baseline (within 1 month) A (8)
New or Worsening Symptoms
154. ● After revascularization (stent or bypass) A (8)
155. ● Post trauma A (8)
156. ● After vein bypass graft
● Surveillance at 6 to 8 months
A (7)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
158. ● After vein bypass graft
● Surveillance every 12 months
A (7)
159. ● After prosthetic bypass graft
● Surveillance every 12 months
A (7)
A  appropriate; ABI  ankle-brachial index; ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; CABG  coronary
artery bypass graft; CHF  congestive heart failure; CT  computed tomography; GI  gastrointestinal; ICA  internal carotid artery; PAD  peripheral
artery disease; PVR  pulse volume recording.
*In the setting of interval development of clinical symptoms in a previously asymptomatic patient or for rapid progression of stenosis during subsequent
follow-up (eg, stenosis category change during a limited period of time), more intensive surveillance may be indicated.
†Carotid artery occlusion to be addressed in the text of the document. Periodic surveillance duplex ultrasound should be performed according to the severity
of stenosis of the contralateral side.
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Indication
Appropriate Use
Score (1-9)
Extracranial Cerebrovascular Ultrasound
Evaluation for Cerebrovascular Disease—Potential Signs and/or Symptoms
4. ● Syncope of uncertain cause after initial cardiovascular evaluation U (5)
Evaluation for Cerebrovascular Disease—Asymptomatic with Comorbidities or Risk Factors for
Carotid Artery Stenosis
10. ● No cervical bruit
● History of neck irradiation 10 years ago
U (5)
11. ● Known renal fibromuscular dysplasia U (5)
Prior to Open Heart Surgery
12. ● Planned coronary artery bypass grafting (CABG) U (6)
13. ● Atherosclerotic disease in other vascular beds (eg, lower extremity PAD, coronary artery disease,
abdominal aortic aneurysm), or history of neck irradiation  10 years ago
● Planned valve repair/replacement surgery (without CABG)
U (6)
14. ● Atherosclerotic risk factors present
● Planned valve repair/replacement surgery (without CABG)
U (6)
15. ● No atherosclerotic risk factors
● Planned valve repair/replacement surgery (without CABG)
U (4)
Follow-Up or Surveillance for Carotid Artery Stenosis—Asymptomatic*†
Surveillance Frequency During First Year
19. ● Moderate ICA stenosis (eg, 50% to 69%)
● At 6 to 8 months
U (6)
19. ● Moderate ICA stenosis (eg, 50% to 69%)
● At 9 to 12 months
U (6)
20. ● Severe ICA stenosis (eg, 70% to 99%)
● At 3 to 5 months
U (5)
20. ● Severe ICA stenosis (eg, 70% to 99%)
● At 9 to 12 months
U (6)
Surveillance Frequency After First Year
21. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● Every 24 months or greater
U (5)
22. ● Mild ICA stenosis (eg, 50%)
● Every 12 months
U (5)
22. ● Mild ICA stenosis (eg, 50%)
● Every 24 months or greater
U (6)
23. ● Moderate ICA stenosis (eg, 50% to 69%)
● Every 24 months or greater
U (6)
24. ● Severe ICA stenosis (eg, 70% to 99%)
● Every 24 months or greater
U (6)
Surveillance After Carotid Artery Intervention
27. ● Following abnormal ipsilateral ICA baseline study
● Surveillance at 3 to 5 months
U (4)
27. ● Following abnormal ipsilateral ICA baseline study
● Surveillance at 9 to 12 months
U (5)
Surveillance Frequency After First Year
28. ● Following normal ipsilateral ICA baseline study
● Surveillance every 24 months or greater
U (5)
29. ● Following abnormal ipsilateral ICA baseline study
● Surveillance every 6 months
U (4)
29. ● Following abnormal ipsilateral ICA baseline study
● Surveillance every 24 months or greater
U (5)
Carotid Duplex Screening Ultrasound
Limited Screening Study for Carotid Artery Plaque—Asymptomatic‡
31. ● Intermediate Framingham risk score
● No prior risk assessment imaging study, such as coronary calcium scoring or carotid IMT mea-
surement
U (4)
33. ● High Framingham risk score U (5)
Screening for Renal Artery Stenosis—Asymptomatic
46. ● Unexplained size discrepancy between kidneys (1.5 cm; in longest dimension) as discovered by
CT or ultrasound
U (4)
Evaluation for Mesenteric Artery Stenosis—Potential Signs and/or Symptoms
Symptomatic
49. ● Post prandial pain or discomfort
● GI evaluation not yet undertaken
U (5)51. ● Unexplained or unintended weight loss U (5)
JOURNAL OF VASCULAR SURGERY
July 2012e40 Mohler III et alTable 10. Continued.
Indication
Appropriate Use
Score (1-9)
52. ● Abdominal or epigastric bruit U (4)
Follow-up Testing for Renal Artery Stenosis—Asymptomatic
54. ● Surveillance of known renal artery stenosis U (6)
Surveillance After Renal or Mesenteric Artery Revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
57. ● During first 12 months after endovascular revascularization
● Surveillance at 6 to 8 months
U (6)
57. ● During first 12 months after endovascular revascularization
● Surveillance at 9 to 12 months
U (6)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
58. ● After first 12 months after endovascular revascularization
● Surveillance every 24 months or greater
U (5)
Aortic and Aorto-Iliac Duplex
Evaluation for Abdominal Aortic Disease—Signs and/or Symptoms
61. ● New onset abdominal or back pain U (6)
69. ● Erectile dysfunction U (4)
Screening for Abdominal Aortic Aneurysm—Asymptomatic
80. ● Age 65 years
● No history of smoking
U (5)
Surveillance of Known Abdominal Aortic Aneurysm
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 6 to 8 months
U (4)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 6 to 8 months
U (4)
85. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance at 3 to 5 months
U (4)
86. ● Aneurysm 5.5 cm in diameter
● Surveillance at 9 to 12 months
U (6)
Asymptomatic or Stable Symptoms, No or Slow Progression During First Year, Surveillance Frequency After First Year
89. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 6 months
U (5)
89. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 24 months or greater
U (6)
90. ● Aneurysm 5.5 cm in diameter
● Surveillance every 24 months or greater
U (5)
Asymptomatic or Stable Symptoms, Rapid Progression During First Year, Surveillance Frequency After First Year
91. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 24 months or greater
U (4)
92. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 24 months or greater
U (4)
93. ● Aneurysm 4.0 to 5.4 cm in diameter
● Surveillance every 24 months or greater
U (4)
94. ● Aneurysm 5.5 cm in diameter
● Surveillance every 12 months
U (5)
Surveillance After Aortic Endograft or Aortoiliac Stenting
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
99. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance at 6 to 8 months
U (5)
99. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance at 9 to 12 months
U (6)
100. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size
● Surveillance at 3 to 5 months
U (6)
101. ● Aortic or iliac artery stents
● Surveillance at 6 to 8 months
U (5)
101. ● Aortic or iliac artery stents
● Surveillance at 9 to 12 months
U (6)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
102. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance every 24 months or greater
U (5)
103. ● Aortic endograft with endoleak and/or increasing residual aneurysm sac size U (5)
● Surveillance every 24 months or greater
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Appropriate Use
Score (1-9)
104. ● Aortic or iliac artery stents
● Surveillance every 12 months
U (5)
104. ● Aortic or iliac artery stents
● Surveillance every 24 months or greater
U (5)
Surveillance of Known Lower Extremity PAD
No Change in Symptom Status (No Revascularization)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
118. ● Mild or moderate disease (eg, ABI 0.4)
● Surveillance at 9 to 12 months
U (4)
119. ● Severe (eg, ABI 0.4)
● Surveillance at 6 to 8 months
U (5)
119. ● Severe (eg, ABI 0.4)
● Surveillance at 9 to 12 months
U (5)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
121. ● Mild or moderate disease (eg, ABI 0.4)
● Surveillance every 24 months or greater
U (4)
122. ● Severe (eg, ABI 0.4)
● Surveillance every 6 months
U (4)
122. ● Severe (eg, ABI 0.4)
● Surveillance every 12 months
U (4)
Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
125. ● After angioplasty  stent placement
● Surveillance at 6 to 8 months
U (6)
125. ● After angioplasty  stent placement
● Surveillance at 9 to 12 months or greater
U (6)
126. ● After vein bypass graft
● Surveillance at 3 to 5 months
U (6)
126. ● After vein bypass graft
● Surveillance at 9 to 12 months
U (6)
127. ● After prosthetic bypass graft
● Surveillance at 3 to 5 months
U (5)
127. ● After prosthetic bypass graft
● Surveillance at 9 to 12 months
U (5)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
128. ● After angioplasty  stent placement
● Surveillance every 24 months or greater
U (5)
129. ● After vein bypass graft
● Surveillance every 6 months
U (5)
129. ● After vein bypass graft
● Surveillance every 24 months or greater
U (5)
130. ● After prosthetic bypass graft
● Surveillance every 24 months or greater
U (5)
Lower Extremity Artery Testing With ABI Only
Screening for Lower Extremity Atherosclerotic Disease—Asymptomatic With Comorbidities
134. ● Age 50 years
● With diabetes
U (5)
Lower Extremity Artery Testing with Duplex Ultrasound Only
Evaluation for Groin Complication After Femoral Access
139. ● Ecchymosis U (4)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Evaluation for Upper Extremity PAD—Potential Signs and/or Symptoms
145. ● Raynaud’s phenomenon U (5)
148. ● Discrepancy in arm pulses or blood pressure discrepancy of 20 mm Hg between arms U (6)
149. ● Periclavicular bruit U (5)
Upper Extremity Arterial Testing—Physiological Testing or Duplex Ultrasound Study
Surveillance of Upper Extremity PAD After Revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
156. ● After vein bypass graft
● Surveillance at 3 to 5 months
U (6)
156. ● After vein bypass graft U (5)
● Surveillance at 9 to 12 months
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157. ● After prosthetic bypass graft
● Surveillance at 6 to 8 months
U (6)
157. ● After prosthetic bypass graft
● Surveillance at 9 to 12 months
U (4)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
158. ● After vein bypass graft
● Surveillance every 6 months
U (4)
158. ● After vein bypass graft
● Surveillance every 24 months or greater
U (5)
159. ● After prosthetic bypass graft
● Surveillance every 6 months
U (4)
159. ● After prosthetic bypass graft
● Surveillance every 24 months or greater
U (4)
ABI ankle-brachial index; CABG coronary artery bypass graft; CT computed tomography; GI gastrointestinal; ICA internal carotid artery; IMT
intima-media thickness; PAD  peripheral artery disease; PVR  pulse volume recording; U  uncertain.
*In the setting of interval development of clinical symptoms in a previously asymptomatic patient or for rapid progression of stenosis during subsequent
follow-up (eg, stenosis category change during a limited period of time), more intensive surveillance may be indicated.
†Carotid artery occlusion to be addressed in the text of the document. Periodic surveillance duplex ultrasound should be performed accordingto the severity
of stenosis of the contralateral side.
‡A screening carotid duplex examination includes assessment for the presence of atherosclerotic plaque within the common and internal carotid arteries using
grey-scale imaging and assessment for stenosis of the proximal internal carotid artery using spectral Doppler. The screening carotid duplex examination is
3 A screening study for carotid artery plaque does notperformed using a limited but clearly defined screening protocol (see ICAVL 2010 standards 5.1.5 ).
include formal measurement of carotid IMT.Table 11. Inappropriate Indications (Median Score 1-3)
Indication
Appropriate Use
Score (1-9)
Extracranial Cerebrovascular Ultrasound
Follow-Up or Surveillance for Carotid Artery Stenosis—Asymptomatic
16. ● Normal prior examination (no plaque, no stenosis) I (1)
Surveillance Frequency During First Year
17. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● At 3 to 5 months
I (1)
17. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● At 6 to 8 months
I (1)
17. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● At 9 to 12 months
I (1)
18. ● Mild ICA stenosis (eg, 50%)
● At 3 to 5 months
I (1)
18. ● Mild ICA stenosis (eg, 50%)
● At 6 to 8 months
I (1)
18. ● Mild ICA stenosis (eg, 50%)
● At 9 to 12 months
I (1)
19. ● Moderate ICA stenosis (eg, 50% to 69%)
● At 3 to 5 months
I (2)
Surveillance Frequency After First Year
21. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● Every 6 months
I (1)
21. ● Plaque without significant stenosis of the ICA (plaque, normal ICA velocity)
● Every 12 months
I (3)
22. ● Mild ICA stenosis (eg, 50%)
● Every 6 months
I (2)
23. ● Moderate ICA stenosis (eg, 50% to 69%)
● Every 6 months
I (3)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
26. ● Following normal ipsilateral ICA baseline study I (2)● Surveillance at 3 to 5 months
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Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
28. ● Following normal ipsilateral ICA baseline study
● Surveillance every 6 months
I (2)
Carotid Duplex Screening Ultrasound
Limited Screening Study for Carotid Artery Plaque—Asymptomatic*
30. ● Low Framingham risk score
● No prior risk assessment imaging study, such as coronary calcium scoring or carotid IMT measurement
I (2)
32. ● Low or intermediate Framingham risk score
● Normal prior risk assessment imaging study, such as coronary calcium scoring or carotid IMT measurement
I (3)
Screening for Renal Artery Stenosis—Asymptomatic
45. ● Atherosclerotic vascular disease in other beds (eg, peripheral artery disease) and well controlled hyperten-
sion
I (3)
Evaluation for Mesenteric Artery Stenosis—Potential Signs and/or Symptoms
Symptomatic
47. ● Evaluate for acute abdominal pain ‘out of proportion to exam’
● Leukocytosis, ‘thumbprinting’, pnuematosis or hemoconcentration and acidosis with or without elevated
amylase, alkaline phosphatase or CPK
I (3)
50. ● Chronic constipation or diarrhea
● GI evaluation not yet undertaken
I (3)
Surveillance After Renal or Mesenteric Artery Revascularization
Asymptomatic
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
57. ● During first 12 months after endovascular revascularization
● Surveillance at 3 to 5 months
I (3)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
58. ● After first 12 months after endovascular revascularization
● Surveillance every 6 months
I (3)
Aortic and Aorto-Iliac Duplex
Evaluation for Abdominal Aortic Disease—Signs and/or Symptoms
60. ● Nonspecific lower extremity discomfort I (3)
66. ● Fever of unknown origin I (3)
67. ● Lower extremity swelling I (2)
71. ● Hypertension I (3)
Screening for Abdominal Aortic Aneurysm—Asymptomatic
81. ● Age 65 years
● No history of smoking
I (3)
Surveillance of Known Abdominal Aortic Aneurysm
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
83. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 3 to 5 months
I (1)
84. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance at 3 to 5 months
I (1)
Asymptomatic or Stable Symptoms, No or Slow Progression During First Year, Surveillance Frequency
After First Year
87. ● Men, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
I (2)
88. ● Women, aneurysm 3.0 to 3.9 cm in diameter
● Surveillance every 6 months
I (2)
Asymptomatic or Stable Symptoms, Rapid Progression During First Year, Surveillance Frequency After First Year
94. ● Aneurysm 5.5 cm in diameter
● Surveillance every 24 months or greater
I (3)
Surveillance After Aortic Endograft or Aortoiliac Stenting
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
99. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance at 3 to 5 months
I (3)
101. ● Aortic or iliac artery stents
● Surveillance at 3 to 5 months
I (2)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
102. ● Aortic endograft without endoleak stable and/or decreasing residual aneurysm sac size
● Surveillance every 6 months
I (3)
104. ● Aortic or iliac artery stents I (2)
● Surveillance every 6 months
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Appropriate Use
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Lower Extremity Artery Testing Using Multi-Level Physiological Testing Alone or Duplex Ultrasound With Single Level ABI
and PVR
Evaluation for Lower Extremity Atherosclerotic Disease—Potential Signs and/or Symptoms
110. ● Nocturnal leg cramps
● Normal pulses
I (2)
111. ● Lack of hair growth on dorsum of foot or toes
● Normal pulses
I (2)
113. ● Lower extremity swelling
● Normal pulses
I (2)
114. ● Diabetes with peripheral neuropathy
● Normal pulses
I (3)
Surveillance of Known Lower Extremity PAD
No Change in Symptom Status (No Revascularization)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
117. ● Normal baseline ABI (no stenosis)
● Surveillance at 3 to 5 months
I (1)
117. ● Normal baseline ABI (no stenosis)
● Surveillance at 6 to 8 months
I (1)
117. ● Normal baseline ABI (no stenosis)
● Surveillance at 9 to 12 months
I (1)
118. ● Mild or moderate disease (eg, ABI 0.4)
● Surveillance at 3 to 5 months
I (2)
118. ● Mild or moderate disease (eg, ABI 0.4)
● Surveillance at 6 to 8 months
I (2)
119. ● Severe (eg, ABI 0.4)
● Surveillance at 3 to 5 months
I (3)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
120. ● Normal baseline ABI (no stenosis)
● Surveillance every 6 months
I (1)
120. ● Normal baseline ABI (no stenosis)
● Surveillance every 12 months
I (1)
120. ● Normal baseline ABI (no stenosis)
● Surveillance every 24 months or greater
I (2)
121. ● Mild or moderate disease (eg, ABI 0.4)
● Surveillance every 6 months
I (2)
121. ● Mild or moderate disease (eg, ABI 0.4)
● Surveillance every 12 months
I (2)
122. ● Severe (eg, ABI 0.4)
● Surveillance every 24 months or greater
I (3)
Surveillance of Lower Extremity PAD After Revascularization (Duplex/ABI)
Asymptomatic or Stable Symptoms
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
125. ● After angioplasty  stent placement
● Surveillance at 3 to 5 months
I (2)
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency After First Year
128. ● After angioplasty  stent placement
● Surveillance every 6 months
I (3)
130. ● After prosthetic bypass graft
● Surveillance every 6 months
I (3)
Upper Extremity Arterial Testing-Physiological Testing or Duplex Ultrasound Study
Surveillance of Upper Extremity PAD After Revascularization
Asymptomatic or Stable Symptoms After Baseline Study, Surveillance Frequency During First Year
157. ● After prosthetic bypass graft
● Surveillance at 3 to 5 months
I (3)
ABI  ankle-brachial index; CABG  coronary artery bypass graft; CPK  creatine phosphokinase; GI  gastrointestinal; I  inappropriate; ICA  internal
carotid artery; IMT  intima-media thickness; ICA  internal carotid artery; PAD  peripheral artery disease; PVR  pulse volume recording.
*A screening carotid duplex examination includes assessment for the presence of atherosclerotic plaque within the common and internal carotid arteries using
grey-scale imaging and assessment for stenosis of the proximal internal carotid artery using spectral Doppler. The screening carotid duplex examination is
3 A screening study for carotid artery plaque does notperformed using a limited but clearly defined screening protocol (see ICAVL 2010 standards 5.1.5).
include formal measurement of carotid IMT.
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The noninvasive vascular laboratory plays a central role
in the evaluation and surveillance of peripheral vascular
disorders. The scope of this document includes common
clinical indications encountered in patients with suspected
or known non-coronary arterial disorders, including ath-
erosclerotic occlusive disease (ie, carotid artery stenosis, lower
and upper extremity peripheral arterial disease, renal and mes-
enteric artery occlusive disease), abdominal aortic aneurysms,
and also less common disorders such as fibromuscular dyspla-
sia, vasospasm, arterial dissection, and arterial trauma. Evalu-
ation of the thoracic aorta is not generally undertaken in the
noninvasive vascular laboratory and is beyond the scope of this
document. The appropriate use of transthoracic echocardiog-
raphy for evaluation of aortic disease is addressed in the 2011
Appropriate Use Criteria for Echocardiography.16
Due to the diversity of peripheral vascular disorders, it
is likely that many potential clinical indications are not
included in this document. Rather than an exhaustive com-
pendium of clinical indications, it is intended that this
document address the most common and important clini-
cal scenarios encountered in the care patients with periph-
eral vascular disease. This document includes ratings for
both duplex ultrasound examinations and physiological
testing studies (when appropriate). This document in-
cludes indications related to arterial disorders only; separate
appropriateness criteria for venous ultrasound and physio-
logical testing, which will also include indications related to
dialysis access, are under development and anticipated in
the near future. It is intended that this document will
provide guidance for clinicians in maximizing the appropri-
ate use of the noninvasive vascular laboratory for the care of
patients with suspected or known peripheral vascular disor-
ders. In addition, it is intended that this document identify
critical evidence gaps in the field and serve as a reference for
policy makers with regard to noninvasive vascular testing.
Appropriate Use Criteria were developed using medical
evidence and supplemented by expert opinion to assess
whether the net benefit or risks of a noninvasive, vascular
laboratory–based, diagnostic test for arterial disease make it
reasonable to perform. The intent of the criteria is to avoid
over- or underutilization, thereby promoting optimal health-
care delivery along with justifying healthcare expenditures and
promoting the best outcome for patients with minimal risk.
The AUC for vascular laboratory testing were devel-
oped as complimentary and are aligned with the ACC/
AHA Guidelines for the Management of Patients with
Peripheral Arterial Disease and the ASA/ACC/AHA mul-
tisocietal Guidelines for the Management of Patients with
Extracranial Carotid and Vertebral Artery disease.7,14 Spe-
cifically, the ACC/AHA PAD and carotid/vertebral guide-
lines include, for each vascular territory, a section on diag-
nostic methods. The current AUC document includes
some of the diagnostic methods for disease investigation such
as ultrasound and physiological testing. Other modalities such
as computed tomography and magnetic resonance are not
covered in the current AUC document. uIt should be noted that the optimal clinical manage-
ent of many common peripheral vascular disorders re-
uires periodic imaging surveillance, both to follow for
isease progression and to determine the time at which a
hreshold for intervention has been reached. In contrast to
any cardiac conditions, peripheral arterial interventions
re often indicated to prevent untoward vascular events in
he patient with severe but asymptomatic vascular disease.
xamples of such indications include repair of a large but
symptomatic abdominal aortic aneurysm to prevent fatal
upture or revascularization of severe asymptomatic inter-
al carotid artery stenosis to prevent ipsilateral stroke. As
uch, there are many more surveillance indications included
n the current AUC document than in the AUC for other
ardiovascular imaging modalities, such as echocardiogra-
hy or nuclear imaging. In addition, it must be noted that
eriodic noninvasive vascular testing is a standard compo-
ent of care following vascular intervention, such as
ollow-up of a lower extremity bypass graft or arterial stent
or significant stenosis or for assessment after endovascular
ortic aneurysm repair to assure aneurysm exclusion and
he absence of endoleak. In some clinical settings, repeat
ntervention may be required based solely upon surveillance
ltrasound findings in the absence of worsening clinical
ymptoms, such as to optimize primary assisted patency of
severely stenotic lower extremity bypass graft.
Summary of Evidence and Call for Additional
esearch. A consensus of “appropriate” was found for
ost vascular studies where clinical signs and symptoms
ere the indication for testing and to establish a “baseline”
fter a revascularization procedure. In general, a follow-up
tudy for a patient with a normal baseline study was deemed
nappropriate. For cerebrovascular disease, a duplex ultra-
ound study was appropriate for hemispheric neurological
ymptoms such as transient ischemic attack or stroke. There
as uncertainty regarding the use of cerebrovascular ultra-
ound for assessment of asymptomatic patients with risk fac-
ors or comorbidities for carotid artery stenosis, but this was
eemed appropriate for assessment of occult cerebrovascular
isease in patients with established atherosclerotic disease in
ther vascular territories. Another area considered uncertain
or cerebrovascular ultrasound was preoperative assessment
rior to cardiac surgery.
For duplex ultrasound to assess for renal artery stenosis,
ppropriate testing indications were hypertension, in-
reased creatinine, and heart failure and for mesenteric
rtery stenosis were patients with postprandial pain and
eight loss who have previously undergone GI evaluation.
he appropriate indications for evaluation of the abdomi-
al aorta and iliac arteries included intermittent claudica-
ion, an aneurysmal femoral or popliteal pulse, a pulsatile
bdominal mass, a decreased or absent femoral pulse, and
n abdominal or femoral bruit, as well as clinical evidence of
theroemboli in the lower extremities, abnormal physio-
ogical testing suggestive of aortoiliac occlusive disease, and
he presence of a thoracic aortic aneurysm. Erectile dys-
unction was considered an uncertain indication of duplex
ltrasound of the aorta and iliac arteries. Inappropriate
R1
1
1
1
1
1
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specific discomfort and swelling in lower extremities, fever
of unknown origin, and hypertension. Surveillance of
known aortic or iliac aneurysms was appropriate but did
depend on size of the vessel and rapidity of enlargement.
Lower or upper extremity physiological testing alone or
duplex ultrasound with single-level ABI and PVR was
appropriate for signs and symptoms of ischemia. Screening
tests for the various vascular territories were appropriate for
abdominal aortic aneurysms and the ratings were generally
consistent with USPSTF recommendations. The screening
of selected populations with the ABI was uncertain and
reflects the paucity of data regarding effect on prevention of
claudication and limb loss. However, it did not address
whether ABI screening would impact the high rate of heart
attack and stroke in patients with PAD. With regard to
carotid artery ultrasound screening, a low Framingham risk
score was an inappropriate indication, whereas an interme-
diate or high Framingham risk score was an uncertain
indication. The uncertain indications noted in all the vas-
cular territories exposes the need for outcome and clinical
effectiveness data to allow for appropriateness certainly.
The current evidence base and clinical practice guide-
lines were used to develop and rate the clinical indications
whenever available, although for certain indications, the
available scientific literature was limited and clinical exper-
tise played a larger role. The writing panel recognizes a
need for more clinical and cost-effectiveness studies focused
specifically on noninvasive vascular testing, and the signifi-
cant number of indications rated by the technical panel as
“uncertain” are reflective of these evidence gaps. The writ-
ing panel identifies the following areas as among those in
greatest need of focused research:
1. Clinical and cost effectiveness of carotid artery duplex
examinations prior to open heart surgery;
2. Cost–benefit analysis and utility of carotid duplex ultra-
sound examination for asymptomatic patients with ath-
erosclerotic vascular disease in other vascular beds (eg,
coronary or peripheral artery disease) and for patients
with multiple atherosclerotic risk factors;
3. Optimal frequency of ultrasound examinations for surveil-
lance of untreated internal carotid artery stenosis, account-
ing for severity of disease on the baseline examination.
4. Optimal frequency of ultrasound examinations for sur-
veillance of abdominal aortic aneurysms, accounting for
size of the aneurysm on the baseline examination and
select patient characteristics (eg, gender).
5. Optimal frequency of ultrasound and physiological test-
ing for surveillance following lower extremity arterial
bypass grafts and endovascular revascularization proce-
dures, accounting for type of procedure (stenting or
bypass), nature of conduit (for bypass grafting), and
anatomic location of the procedure.
6. Comparative effectiveness of duplex ultrasound versus other
imaging modalities for surveillance after aortic endografting.EFERENCES
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